Skip Ribbon Commands
Skip to main content
Gonorrhea Guidelines

Guidelines for Testing and Treatment of Gonorrhea in Ontario, 2013  

Guidelines for Testing and Treatment of Gonorrhea in OntarioGonorrhea is the second most commonly reported sexually transmitted infection in Ontario and North America. Left untreated, gonorrhea can lead to a host of complications including pelvic inflammatory disease, infertility, and blood stream infections. Cephalosporin, the last available class of antibiotics recommended for the treatment of gonorrhea, have been failing worldwide. In response to Ontario and global clinical failures, Public Health Ontario's new guidelines recommend an injectable drug (ceftriaxone), in combination with a pill (azithromycin).

Public Health Ontario's Guidelines for Testing and Treatment of Gonorrhea in Ontario provide the evidence, rationale, and recommendations to effectively diagnose and treat persons infected with N. gonorrhea. The recommendations are based on current scientific evidence, Ontario epidemiology and antimicrobial susceptibility profiles of N. gonorrhea, and available laboratory testing methods in Ontario. The guidelines cover:  

  • Laboratory testing recommendations, including when to perform a Gram stain, bacterial culture or nucleic acid amplification testing (NAAT); 
  • Treatment recommendations for uncomplicated urogenital, rectal and pharyngeal N. gonorrhea infections; and
  • Recommendations for follow-up of N. gonorrhea infections, including public health reporting, testing
    and treatment of sexual contacts,
    indications for test of cure, and follow-up testing. 

Ontario Ministry of Health and Long-Term Care Resources:

Uncontrolled print copy. Valid only on day of Print: [date]
Page updated on [date/time] 08/07/2015 11:40 AM
© , Ontario Agency for Health Protection and Promotion